Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc > Penny Stock Investors and Cash Flow
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by MementoMorion Aug 12, 2010 6:58pm
476 Views
Post# 17346737

RE: RE: RE: Penny Stock Investors and Cash Flow

RE: RE: RE: Penny Stock Investors and Cash Flow> So why couldn’t Isotechnika say to Paladin, finish psoriasis submission in Canada

If I recall correctly, Jonothan Goodman (= Paladin) suggested (in response to the same question) at last year's annual meeting that the costs for finishing psoriasis were too much for Paladin to take on.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities